Meeting
2017 Gastrointestinal Cancers Symposium
A prospective, multicenter, randomized clinical trial of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting (PURE FIST).
Authors
Jaw-Yuan Wang
Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Clinical Trial Registration Number
NCT02256800
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 625)
DOI
10.1200/JCO.2017.35.4_suppl.625
Abstract #
625
Poster Bd #
E21
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Genotype-directed phase II study of irinotecan dosing in metastatic colorectal cancer (mCRC) patients receiving FOLFIRI + bevacizumab: The GENIC study.
First Author: Grant Richard Williams
Poster
2022 ASCO Annual Meeting
Biweekly mXELIRI versus FOLFIRI in combination with bevacizumab as the first-line treatment for metastatic colorectal cancer (EXIST): A multicenter, randomized, open-label, phase 2 study.
First Author: Zhichao Jiang
Poster
2019 Gastrointestinal Cancers Symposium
A randomized phase II study comparing oral S-1 plus 24-hour infusion of irinotecan (Iri) and bevacizumab (Bev) with FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer (MCRC).
First Author: Sotaro Sadahiro
Poster
2016 Gastrointestinal Cancers Symposium
Bevacizumab effectiveness and primary tumor location in metastatic colorectal cancer patients.
First Author: Wen-zhuo He